AI GOVERNANCE IN LIFE SCIENCES
You Are Deploying AI Agents. Who Is Managing Them?
As pharma and biotech organizations race to deploy AI Agents across clinical operations, pharmacovigilance, and regulatory workflows, a critical infrastructure layer is being skipped: the AI Management System. The FDA, EMA, and ISO 42001 are all pointing to the same gap. It is time to build the control plane before the compliance event forces the conversation.
By Dinesh Kashyap, CEO, Cloudbyz
Clinical Technology & AI Strategy | April 2026
01 THE MOMENT WE ARE IN
For the better part of three years, AI in life sciences was largely aspirational. Organizations ran proof-of-concept projects. Vendors made bold claims. Regulatory affairs teams asked cautious questions about validation. The general posture was one of careful experimentation.
That phase is over.
In 2025, life sciences organizations are deploying AI Agents in production. Clinical data managers are using AI to auto-classify trial master file documents. Pharmacovigilance teams are running AI-assisted case processing for adverse event narratives. Regulatory writers are leveraging AI to accelerate CTD module drafting. Medical monitors are deploying AI to flag site-level risk signals in real time.
The speed of deployment is accelerating. And with that acceleration comes a risk that is not being discussed loudly enough: organizations are deploying AI Agents without the infrastructure to manage them.
|
THE CORE RISK Deploying AI Agents without an AI Management System (AIMS) is the operational equivalent of running clinical trials without a CTMS. You have activity, but no oversight. You have output, but no audit trail. You have capability, but no governance. |
This is not a theoretical concern. It is a practical, present-tense compliance and operational risk. The FDA and EMA have both issued guidance signals. ISO 42001 provides a ready framework. And the organizations that build the governance infrastructure now will be in a fundamentally different position than those who wait.
02 WHAT REGULATORS ARE ALREADY SAYING
It would be a mistake to read the current regulatory guidance on AI as preliminary or non-binding. Both the FDA and EMA have moved well past awareness into active expectation-setting. Understanding what each body has said is essential context for any life sciences organization building an AI strategy.
The FDA's AI Action Plan, along with its series of discussion papers and draft guidances, has established several principles that directly affect how AI Agents must be governed in drug development and clinical operations contexts.
The FDA has signaled a predetermined change control plan framework for AI-enabled software as a medical device, requiring that organizations document in advance how AI systems may change, under what conditions revalidation is required, and how changes will be tracked. While this framework originated in the SaMD space, its principles are increasingly being applied to AI tools used in GxP workflows.
Critically, FDA reviewers have begun asking questions about AI tools used in clinical data management and regulatory submissions. Organizations that cannot demonstrate how an AI system was validated, how its outputs were reviewed, and how its performance has been monitored over time are at increasing risk during inspections.
|
FDA PRINCIPLE Transparency and Explainability
|
EMA PRINCIPLE Lifecycle Management
|
ISO PRINCIPLE Human Oversight
|
The European Medicines Agency's Reflection Paper on AI represents one of the most comprehensive regulatory statements on the topic to date. It establishes a set of principles that organizations deploying AI in any part of the medicinal product lifecycle must take seriously.
The EMA paper identifies four foundational requirements: that AI systems be fit for purpose, that data used to train or operate them be of appropriate quality, that AI decisions be explainable to a level appropriate to the stakes involved, and that human oversight be genuinely embedded, not theatrical.
The EMA is also explicit about the risks of AI systems that perform well in training but degrade in production. This concept, which data scientists call distribution shift or model drift, is treated not as a technical footnote but as a core governance concern requiring active monitoring programs.
|
EMA KEY EXPECTATION The EMA Reflection Paper states that AI systems in the medicinal product lifecycle must be subject to documented governance arrangements, including performance monitoring, change management, and clear accountability for AI-generated outputs. This language maps directly to what an AIMS is designed to provide. |
What is notable about both the FDA and EMA guidance is how much they converge. Both emphasize transparency. Both require lifecycle management. Both demand human oversight. Both expect organizations to demonstrate, not merely assert, that AI systems are performing as intended. This convergence is not coincidental. It reflects a global regulatory consensus that is forming quickly and will only harden as AI becomes more deeply embedded in regulated workflows.
03 ISO 42001 AND THE AIMS FRAMEWORK
ISO 42001 is the international standard for AI Management Systems. Published by the International Organization for Standardization in 2023, it provides a systematic framework for organizations to establish, implement, maintain, and continuously improve their management of AI systems. For life sciences organizations, it is the most directly applicable governance standard available today.
Understanding what ISO 42001 actually requires, as distinct from what many organizations assume it requires, is important. It is not a technical standard that specifies how to build AI models. It is a management systems standard that specifies how organizations should govern AI at an institutional level.
|
01 Organizational Context Understand internal and external factors affecting AI use. Identify stakeholders and their requirements. Define the scope of the AIMS clearly and document it. |
02 Risk-Based Classification Classify AI systems by risk level. Higher risk applications in patient safety or regulatory submission require proportionally more rigorous controls and oversight. |
|
03 Documentation Requirements Maintain documented information about AI system objectives, training data provenance, validation activities, performance baselines, and ongoing monitoring results. |
04 Continuous Improvement Establish feedback loops for AI system performance. Conduct periodic reviews. Update controls when performance degrades or operating context changes materially. |
|
05 Accountability Structures Define who is responsible for each AI system. Establish clear ownership for governance, validation, monitoring, and incident response at the system level. |
06 Bias and Fairness Controls Identify and assess potential bias in AI systems. Implement controls to detect and mitigate bias, particularly where AI outputs affect clinical or safety decisions. |
For a pharma or biotech organization deploying AI Agents across CTMS, eTMF, EDC, and pharmacovigilance workflows, ISO 42001 provides the management architecture. The control plane technology provides the operational infrastructure to execute against that architecture.
ISO 42001 is not the ceiling of AI governance in life sciences. It is the floor.
04 THE CONTROL PLANE PROBLEM
There is a pattern emerging in life sciences AI deployments that closely mirrors what happened in early cloud adoption. Organizations moved fast on capability. They deployed workloads, connected systems, and realized efficiency gains. What they deferred was governance: security controls, cost visibility, access management, audit trails. The reckoning came later, under pressure, and was far more expensive to address retroactively than it would have been to build in from the start.
The same dynamic is playing out with AI Agents today.
Most organizations deploying AI Agents are focused entirely on the model layer: which foundation model to use, how to prompt it, how to integrate it with source systems. Far fewer are thinking about the control plane, the infrastructure layer that sits above individual AI models and provides organization-wide visibility and governance.
Without a control plane, what you have is not AI governance. What you have is AI sprawl.
|
SIGNS OF AI SPRAWL Multiple AI tools deployed by different teams with no central registry. No consistent approach to validation across systems. No visibility into aggregate AI spend. No mechanism to detect when an agent's accuracy is degrading. No audit trail that would satisfy an FDA inspector asking how an AI-classified document ended up in a regulatory submission. |
05 SIX DIMENSIONS OF AN EFFECTIVE AIMS
An effective AI Management System in a life sciences context must address six distinct operational dimensions. Each maps to specific regulatory requirements and to real operational risks that organizations face when they skip this infrastructure layer.
|
Dimension |
What It Covers |
Regulatory Relevance |
|
01 PROVISIONING |
Which agents are authorized to run, in which workflows, with which data access, by which users or roles. Agent registration, approval workflows, and decommissioning protocols. |
21 CFR Part 11 access controls; GxP role-based access; EMA accountability requirements |
|
02 COST MONITORING |
Token consumption per agent, per workflow, per trial. API spend attribution. ROI measurement against efficiency benchmarks. Budget controls and alerting. |
Organizational governance; investor and board visibility; exit due diligence readiness |
|
03 HEALTH & ACCURACY |
Output quality scoring, hallucination detection, confidence thresholds, model drift monitoring. Automated alerts when accuracy falls below defined thresholds. Revalidation triggers. |
FDA lifecycle management; EMA performance monitoring; ISO 42001 continuous improvement |
|
04 OBSERVABILITY |
Full audit trails of agent decisions, inputs, outputs, and human review actions. Traceability from AI output to downstream use. Replay capability for incident investigation. |
FDA inspection readiness; 21 CFR Part 11 audit trail requirements; GxP documentation standards |
|
05 COMPLIANCE |
GxP alignment scoring, ISO 42001 maturity tracking, validation status across the agent portfolio, evidence package generation for audits and inspections. |
FDA, EMA, PMDA regulatory inspections; ISO 42001 certification; SOC 2 Type II |
|
06 INCIDENT MGMT |
Defined response protocols when AI output causes a quality event. Escalation paths. Root cause analysis support. Change control integration for model updates following an incident. |
CAPA requirements; deviation management; EMA accountability principles |
None of these dimensions is optional in a regulated environment. An organization that has strong observability but no provisioning controls has a half-built system. The AIMS must address all six dimensions coherently.
06 AI AGENT LIFECYCLE IN A GXP ENVIRONMENT
One of the most common misconceptions about AI governance in life sciences is that it is primarily a deployment concern. In reality, governance requirements span the entire AI Agent lifecycle.
01. Use Case Assessment and Risk Classification
Before an AI Agent is developed or procured, it must be classified by risk. An agent that classifies eTMF documents carries different risk than one that flags potential adverse events. Risk classification determines the depth of validation required, the frequency of monitoring, and the level of human oversight that must be embedded in the workflow.
02. Validation and Qualification
AI Agents used in GxP workflows require documented validation analogous to, though distinct from, traditional computer system validation. This includes defining intended use, establishing performance benchmarks, testing against representative data sets, and documenting the validation in a format that would satisfy a regulatory inspector.
03. Controlled Deployment and Provisioning
Deployment must be controlled through a provisioning process that enforces role-based access, documents the production configuration, and establishes a baseline against which future changes will be measured. Informal deployment is incompatible with GxP requirements.
04. Continuous Monitoring and Performance Management
Post-deployment monitoring is where most organizations have the largest gap. AI models are sensitive to changes in input data distribution and operating context. Continuous monitoring, with defined thresholds and automated alerting, is required to detect degradation before it affects regulated outputs.
05. Change Control for Model Updates
When an AI Agent is updated, whether through a model version change, a prompt modification, or a change to its data inputs, that change must flow through a formal change control process aligned to FDA predetermined change control plan principles.
06. Periodic Review and Revalidation
At defined intervals, and whenever a significant change in operating context occurs, AI Agents in GxP workflows should undergo periodic review to assess whether the original validation remains current and performance benchmarks are still being met.
07. Decommissioning
Retiring an AI Agent requires the same rigor as deploying one. Documentation must be archived. Audit trails must be preserved for the required retention period. Downstream workflows that relied on the agent must be assessed and updated.
07 HOW TO BUILD YOUR AIMS
The good news is that building an AI Management System does not require starting from zero. ISO 42001 provides the framework. Existing quality management systems, computer system validation procedures, and GxP documentation standards provide the foundation.
The first step is understanding what AI systems are currently deployed or in active development across the organization. In most organizations, this inventory will be larger than leadership expects. AI tools embedded in commercial software, custom agents developed by individual teams, and externally hosted AI services used informally all need to be surfaced.
Once the inventory exists, each AI system should be classified by risk using a framework aligned to ISO 42001 and informed by the FDA and EMA principles. A simple three-tier classification, low, medium, and high, based on the nature of the AI output and its proximity to regulated decisions or patient safety, provides a workable starting point.
With the inventory and classifications in place, the organization can establish its control plane. This includes defining the provisioning process for new AI Agents, implementing monitoring infrastructure across the six dimensions described earlier, and establishing the documentation standards required for audits and inspections.
|
CLOUDBYZ AIMS ARCHITECTURE For organizations on the Salesforce platform, Cloudbyz provides a native AIMS control plane that integrates across the eClinical suite, including CTMS, eTMF, EDC, and Safety and PV. This enables unified AI governance across the clinical development lifecycle without requiring separate infrastructure investment. ISO 42001 alignment is built into the framework from the ground up. |
Governance infrastructure without clear accountability structures will not function. Every AI Agent in production must have a defined owner who is responsible for its validation status, its ongoing monitoring, and its compliance posture.
An AIMS that operates in isolation from the broader quality management system will create friction and gaps. The AIMS must be integrated with CAPA workflows, deviation management, change control, and training processes.
08 THE COST OF NOT ACTING
The objection most commonly raised against investing in AIMS infrastructure early is a resource allocation argument. Organizations are resource-constrained. Building governance infrastructure competes for attention and budget with building product, running trials, and generating revenue.
The actual trade-off is between investing in governance now, at a time and pace of your choosing, or investing in remediation later, under regulatory pressure, at emergency cost and with reputational consequences.
The scenarios that should focus attention are not hypothetical:
|
EXIT READINESS NOTE For life sciences organizations preparing for M&A or buy-out events, AI governance documentation is increasingly a due diligence item. Acquirers with regulatory expertise are asking specific questions about AI validation status, monitoring programs, and ISO 42001 alignment. Organizations that cannot answer these questions are accepting a valuation discount that could have been avoided. |
09 CONCLUSION
AI Agents will transform clinical operations, safety monitoring, and regulatory workflows in life sciences. That transformation is already underway. The organizations that navigate it most successfully will not simply be those who deploy the most capable agents. They will be those who deploy agents responsibly, within a governance framework that satisfies FDA and EMA expectations, meets ISO 42001 requirements, and provides the operational visibility needed to manage a growing AI portfolio with confidence.
The AI Management System is not a Phase 2 project. It is not something to build after you have proven out your AI Agents in production. It is the foundational infrastructure that makes responsible AI deployment possible in the first place.
The regulators have spoken. The standard exists. The framework is proven. The only remaining question is whether your organization will build its AIMS before a compliance event makes the decision for you.